Migranal (Dihydroergotamine Mesilate)

Dihydroergotamine mesilate, the active ingredient in Migranal, is an ergot alkaloid presented as a 1 mg per spray nasal spray for nasal use. Approved in the European Union, it is indicated for the acute treatment of migraine attacks in adults, delivering rapid relief of headache and associated symptoms.

GNH USA supplies Migranal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring reliable supply chain management across global markets.

Dihydroergotamine mesilate is used to abort acute migraine attacks by modulating serotonergic and vascular pathways involved in migraine pathophysiology.

- Acute migraine: provides rapid relief of headache pain and associated nausea or photophobia. - Migraine attacks: aborts ongoing migraine episodes when administered at onset. - Status migrainosus: may be employed for severe, prolonged migraine attacks unresponsive to other therapies.

Dihydroergotamine mesilate may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nasal irritation or burning sensation. - Nausea or vomiting. - Dizziness or light‑headedness. - Dry mouth. - Fatigue or drowsiness.

Serious or Rare Side Effects: - Severe vasospasm leading to hypertension or myocardial ischemia. - Peripheral ischemia or gangrene. - Anaphylaxis or severe allergic reaction. - Serotonin syndrome, especially when combined with serotonergic agents.

When prescribing Migranal, clinicians should consider several precautionary measures to minimize risk.

- Cardiovascular disease: avoid use in patients with coronary artery disease or uncontrolled hypertension. - Peripheral vascular disease: contraindicated in individuals with severe peripheral arterial insufficiency. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk. - Drug interactions: monitor closely when combined with serotonergic or ergot‑containing medications. - Hepatic impairment: dose adjustment may be required in severe liver disease. - Store below 25°C: keep in the original pack, protect from moisture and light.

Dihydroergotamine mesilate can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension and serotonin syndrome. - Other ergot derivatives: additive vasoconstrictive effects. - Serotonergic agents (SSRIs, SNRIs, triptans): increased risk of serotonin syndrome.

Moderate Interactions (Monitor Closely):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise dihydroergotamine levels. - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect. - Antihypertensive drugs: potential additive blood pressure changes.